نتائج البحث - Jingky Lozano-Kühne

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

    What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? حسب Seamus Kent, Iryna Schlackow, Jingky Lozano-Kühne, Christina Reith, Jonathan Emberson, Richard Haynes, Alastair Gray, Alan Cass, Colin Baigent, Martin Landray, William G. Herrington, Borislava Mihaylova

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The Heat Shock Protein HSP70 Promotes Mouse NK Cell Activity against Tumors That Express Inducible NKG2D Ligands

    The Heat Shock Protein HSP70 Promotes Mouse NK Cell Activity against Tumors That Express Inducible NKG2D Ligands حسب Leslie Elsner, Vijayakumar Muppala, Mathias Gehrmann, Jingky Lozano-Kühne, Dörthe Malzahn, Heike Bickeböller, Edgar Brunner, Marta Zientkowska, Thomas Herrmann, Lutz Walter, Frauke Alves, Gabriele Multhoff, Ralf Dressel

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes

    Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes حسب Paula Cunnea, Edward Curry, Elizabeth L. Christie, Katherine Nixon, Chun Hei Kwok, Ahwan Pandey, Ratri Wulandari, Kerstin Thol, Jennifer Ploski, Cristina Morera-Albert, Stephen McQuaid, Jingky Lozano-Kühne, James J. Clark, Jonathan Krell, Euan A. Stronach, Iain A. McNeish, David D.L. Bowtell, Christina Fotopoulou

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

    Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer حسب R. Charles Coombes, P. D. Badman, Jingky Lozano-Kühne, X. Liu, Iain R. Macpherson, Ishtiaq Husain Zubairi, Richard D. Baird, Nitzan Rosenfeld, Javier Garciá Corbacho, Nicola Cresti, Ruth Plummer, Andrew J. Armstrong, R. Allerton, Dónal Landers, H. Nicholas, L. McLellan, Andrew Kean Seng Lim, Florent Moulière, Olivier E. Pardo, Veronica Ferguson, Michael J. Seckl

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: